Lupus & antiphospholipid syndrome
Lower-dose glucocorticoid therapy achieves comparable outcomes in Japanese patients with lupus nephritis
Main finding · CRR rateResult — go to the resultRisk difference 13.1% 95% CI −9.4% to 35.6%Authors' conclusion
A reduced initial GC dose of 0.4-0.6 mg/kg/day achieved renal outcomes comparable to conventional dosing in Japanese patients with LN.
Study context
- Population
- Japanese patients with proliferative lupus nephritis (LN) (class III or IV ± V) diagnosed via renal biopsy23 per group after propensity score matching (PSM)
- Participants
- 344 patients
- Exposure
- Lower initial glucocorticoid (GC) dose vs conventional dose
- Low-dosen = 23
- Conventional-dosen = 23reference
- Outcome
- Complete renal response (CRR), defined according to the BLISS-LN trial criteria
- Follow-up
- 12 months
Methodological detailsmulticentre, propensity-score matched (1:1), non-inferiority
- Multicentre
- Propensity-score matched (1:1)
- Non-inferiority
Main finding
CRR rate
Risk difference
13.1%
95% CI −9.4% to 35.6%
By group
Low-dosevs Conventional-dose
risk difference 13.1% (95% CI −9.4% to 35.6%)
As reported in the abstract
Observational data: associations, not effects.
Further findings
GC doses over time
- GC doses differed significantly during the initial 3 months, comparable between groups after 6 months
Original publication
Lower-dose glucocorticoid therapy achieves comparable outcomes in Japanese patients with lupus nephritis. Lupus. Published 6 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →